araag2/HINT huggingface dataset:
Clinical trial NCT00570479 (phase 1, status: completed)
Conditions: uveitis, posterior, glaucoma
ICD codes: G83.83, H15.033, H30.23, G46.2, H15.031, H15.032, H15.039, H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: anecortave acetate
SMILES: [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

        Approximately 24 patients with recent implantation of the Retisert implant who meet the
        inclusion/exclusion criteria defined below will be enrolled in the study. They will be
        identified from the current and future patients of the clinical practices.

          -  Patients must be willing to sign an informed consent form, able to make the required
             study visits, and able to follow instructions.

          -  Patient must be at least 12 years of age.

          -  Implantation of a Retisert implant in the last 12 weeks.

        Exclusion Criteria:

          -  Patient has history of any medical condition which would preclude scheduled study
             visits or completion of the study (i.e., unstable cardiovascular disease)

          -  Patient has insertion of a scleral buckle in the study eye.

          -  Patient has known medical history of allergy or sensitivity to the steroid family of
             drugs.

          -  Patient is on anticoagulant therapy, with the exception of aspirin and antiplatelet
             therapy. Patient has a medical history of a bleeding disorder.

          -  Patient has clinical evidence of scleral thinning.
Clinical trial NCT00384553 (phase 1/phase 2, status: unknown status)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, dhap, tec, autologous stem cell transplantation
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage
             I-IV

          -  pretreatment with systemic therapy

          -  18-65 years of age

          -  Performance status:ECOG 0-2

          -  Granulocyte count >1.5/µm3, Platelet count >100/µm3

          -  Creatinine -Clearance ≥ 1 ml/sec

          -  GPT/GOT ≤ 1.5 x normal (except tumour related)

          -  Bilirubine < 22 µmol/l

          -  no participation in another study 3 month before and during this study

          -  informed consent

        Exclusion Criteria:

          -  Second neoplasia in history or existing except basalioma or squamous epithelium
             carcinoma of the skin or removed cervical intraepithelial neoplasia

          -  CNS- involvement by lymphoma

          -  respiratory Partial- or global insufficiency

          -  cardiac insufficiency (NYHA-Stage 3-4, EF < 30 %)

          -  severe neurological or psychiatric disease

          -  pregnancy

          -  HIV positivity ,active virus hepatitis, bacterial infection

          -  No follow up procedures ensured
Clinical trial NCT00651365 (phase 1, status: terminated)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: jnj-38877605
SMILES: CN1C=C(C=N1)C1=NN2C(C=C1)=NN=C2C(F)(F)C1=CC=C2N=CC=CC2=C1
Reason stopped: 
    early termination due to increase in serum creatinine levels and minimal pd activity.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed advanced or refractory solid tumor no longer eligible for approved therapies

          -  Eastern Cooperative Oncology Group performance status test score of <=2

          -  Must meet protocol lab criteria which will include lab assessment of adequate bone
             marrow function, liver function, and renal function.

        Exclusion Criteria:

          -  Any medical condition that requires wound healing during the study (for example
             chronic leg ulcers, gastric ulcer disease, or expected major surgery)

          -  Major surgery within 3 weeks before enrollment

          -  Decreased or deficient coagulability of blood (for example genetic defects such as
             protein Z deficiency) or compliance problems in subjects required to take
             anticoagulants (e.g., coumarin derivates, acetylsalicylic acid) which could result in
             decreased or deficient coagulability

          -  Chemotherapy (for nitrosoureas and mitomycin C within 6 weeks), radiotherapy,
             immunotherapy, or any other investigational agent within 3 weeks before study drug
             administration

          -  antibody therapy within 3 months before administration of JNJ-38877605

          -  brain metastases

          -  History of uncontrolled heart disease within 12 months before enrollment or any
             protocol-defined cardiovascular abnormalities

          -  Patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Clinical trial NCT00405639 (phase 1/phase 2, status: completed)
Conditions: heart failure, asymptomatic systolic dysfunction
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0, A52.2, E28.319, R31.21, Z78.0, E89.40, Z14.01, I83.90
Drugs: nesiritide, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with an ejection fraction of less than 45%

          -  No clinical signs or symptoms of congestive heart failure

          -  Ability to walk a minimal distance of > 450 meters on a 6-minute walk. If the subject
             is not able to walk 450 meters due to pain in hips and knees and not fatigue or
             shortness of breath, they will still qualify for the protocol.

          -  The subjects will all be on stable doses of an angiotensin converting enzyme (ACE)
             inhibitor for two weeks prior to the active study date.

          -  Therapy with other vasodilators, beta-receptor antagonists, digoxin and antiarrhythmic
             medications will be allowed, however, all medications must be at stable doses two
             weeks prior to the study date.

        Exclusion criteria:

          -  Myocardial infarction within 3 months of screening

          -  Unstable angina within 14 days of screening, or any evidence of myocardial ischemia

          -  Significant valvular stenosis, hypertrophic, restrictive or obstructive
             cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy
             proven active myocarditis

          -  Severe congenital heart diseases

          -  Sustained ventricular tachycardia or ventricular fibrillation within 14 days of
             screening

          -  Second or third degree heart block without a permanent cardiac pacemaker

          -  Stroke within 3 months of screening, or other evidence of significantly compromised
             central nervous system (CNS) perfusion

          -  Total bilirubin of > 1.5 mg/dL or other liver enzymes >1.5 times the upper limit of
             normal

          -  Serum creatinine of > 3.0 mg/dL

          -  Serum sodium of < 125 milliequivalent (mEq)/dL or > 160 mEq/dL

          -  Serum potassium of < 3.5 mEq/dL or > 5.0 mEq/dL change to 5.3

          -  Serum digoxin level of > 2.0 ng/ml

          -  Systolic pressure of < 85 mmHg

          -  Hemoglobin < 10 gm/dl
Clinical trial NCT00610194 (phase 1, status: completed)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: rdea119
SMILES: [H][C@@](O)(CO)CC1(CC1)S(=O)(=O)NC1=C(OC)C=C(F)C(F)=C1NC1=C(F)C=C(I)C=C1
Eligibility criteria:

        Inclusion Criteria: - Histological or cytological confirmed solid tumor. - Advanced
        metastatic or locally recurrent disease for which no proven effective therapy exists. - In
        the expanded MTD cohort, a minimum of 10 patients must have an accessible tumor that is
        amendable to biopsy (cut or needle) at the start and during the study. For patients not in
        the biopsy group, a block from the patient's original diagnostic biopsy/excision, if
        available, may be used for genotype analysis. - ECOG performance status of 0-1. - Life
        expectancy of > or equal to 3 months. - Acceptable hematology, clinical chemistry, and
        coagulation laboratory values. - Patient must be acceptable for treatment and follow up
        according to the Investigator. - Patent must have agreed to and signed the Informed
        Consent. - Patient has within normal range cardiac function as measured by echocardiogram
        or MUGA scan. Exclusion Criteria: - Use of investigational agents or devices within the
        last 28 days. - Major surgery within 30 days of start of study. - Patients with documented
        CNS metastasis who are not off steroids and other CNS therapies - Evidence of uncontrolled
        active infections. - Other serious medical or psychiatric illness. - Significant cardiac
        dysfunction including congestive heart failure (NYHA Class III or IV); myocardial
        infarction or ventricular tachyarrhythmia within the last 6 months; major conduction
        abnormalities unless corrected with a cardiac pacemaker; prolonged QTc >460msec. - Patients
        with known hypersensitivity to any of the drugs or components given in this protocol. -
        Pregnancy. - Women or men of childbearing potential not willing to use effective
        contraception, including barrier protection. - Patients with abdominal fistula, GI
        perforation, intra-abdominal abscess, or small bowel resection, any of which is within 6
        months of study entry. - Patients with abdominal radiation resulting in chronic diarrhea. -
        Because RDEA119 is primarily metabolized by CYP3A4 and CYP2C19, inhibitors and inducers of
        these enzymes should be avoided. - Patients with known HIV infection will be excluded.
Clinical trial NCT00606879 (phase 1, status: terminated)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: sgx523 capsules
SMILES: CN1C=C(C=N1)C1=NN2C(SC3=CC=C4N=CC=CC4=C3)=NN=C2C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has the ability to understand, able, willing to comply with study procedures
             and follow up visits, and has provided written consent

          -  Pathologic evidence of solid tumor

          -  Failed standard therapy and deemed by the Investigator to be suitable for
             participation into the trial

          -  Laboratory values (obtained within 10 days prior to enrollment): ANC: >= 1.5 × 109/L;
             Platelets: >= 100 × 109/L; Hemoglobin: >= 10.0 g/dL (without transfusions); Bilirubin:
             within normal range; AST, ALT, and alkaline phosphatase: <= 2.5 x ULN without tumor
             liver involvement; Serum creatinine: within normal limits; Calculated creatinine
             clearance: >= 60 mL/min/1.73 m2 for patients with creatinine > Institutional Normal
             Values; PT/PTT/INR: within normal limits..

          -  Have IHC evidence of phospho-MET expression on tumor material no more than 12 months
             old. This is a requirement only for entry into the MTD dose expansion phase.

          -  Have no residual toxic effects of previous therapy, and undergo a washout period of at
             least 5 half-lives from the time of administration of the previous therapy.

        Exclusion Criteria:

          -  Pregnant, lactating, or may become pregnant

          -  Cardiac disease requiring medical therapy

          -  Have had a major surgery within 4 weeks prior to Day 1 of the study

          -  Have an active, uncontrolled bacterial, viral, or fungal infection that requires
             ongoing systemic therapy

          -  Have a known active infection with HIV, hepatitis B or C

          -  Have psychiatric or seizure disorders that would require therapy or interfere with
             study participation

          -  Have other severe concurrent nonmalignant disease that could compromise protocol
             objectives, including malabsorptive conditions

          -  Patients receiving prohibited medications as listed in Appendix E, including drugs
             categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high
             potential risk of liver toxicity

          -  Have known allergy to SGX523 formulation or its excipients (croscarmellose sodium,
             lactose monohydrate and magnesium steareate)

          -  Patients receiving anti-coagulant therapy
Clinical trial NCT00626704 (phase 1/phase 2, status: completed)
Conditions: locally advanced or metastatic, unresectable soft tissue sarcoma, sarcoma, soft tissue sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32, C46.1
Drugs: amg 655, doxorubicin
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed soft tissue sarcoma

          -  Locally advanced, recurrent, or metastatic, unresectable disease

          -  Measurable disease according to modified RECIST

          -  ECOG performance status of 0 or 1

          -  Men or women at least 18 years of age

          -  Adequate hematological, renal, hepatic, and coagulation function

        Exclusion Criteria:

          -  Prior treatment with anthracyclines

          -  Uncontrolled cardiovascular disease
Clinical trial NCT01921712 (phase 1, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: pur0200, pur0200 placebo, active comparator
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  A clinical diagnosis of moderate to severe COPD according to the following criteria:

               -  Current or ex-smokers with at least 10 pack-year smoking history

               -  Post-bronchodilator FEV1 >/= 35% and </= 80% of predicted normal value

               -  Post-bronchodilator FEV1/FVC (forced vital capacity) ratio <0.70

               -  Post-bronchodilator improvement in FEV1 >/= 100 mL

        Key Exclusion Criteria:

          -  Current evidence or recent history of clinically significant or unstable disease
             (other than COPD)

          -  Current diagnosis of asthma

          -  Presence of history of clinically significant allergy requiring treatment

          -  COPD exacerbation within 6 weeks

          -  Use of daily oxygen therapy > 10 hours

          -  Thoracotomy with pulmonary resection

          -  Use of systemic steroids within 3 months

          -  Lower respiratory tract infection within 30 days

          -  Upper respiratory tract infection within 30 days requiring treatment with antibiotics

          -  History of tuberculosis, bronchiectasis, or other non-specific pulmonary disease

          -  Prolonged corrected QT (QTc) interval >450 msec males and >470 msec females, or
             history of long QT syndrome
Clinical trial NCT01049451 (phase 1, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: acth, methylprednisolone
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Clinically definite multiple sclerosis defined by McDonald Criteria.

          2. Between 18-65 years of age.

          3. Subject must able to understand and sign the IRB- approved informed consent form prior
             to the performance of any study-specific procedures and is willing to comply with the
             required scheduling and assessments of the protocol, including self-administration of
             study drug (if assigned to the ACTH arm).

          4. Subjects who are women of childbearing potential, must have a negative serum pregnancy
             test at the screening visit, and must be willing to practice a reliable birth-control
             method.

          5. Subjects must have at least one MS relapse within last year and/or at least one new T2
             or Gadolinium-enhanced lesion on MRI while on stable interferon therapy.

          6. EDSS (Expanded Disability Status Scale) score of 3.0 - 6.5

          7. Currently on one of the approved beta-interferon drugs (Avonex, Betaseron, or Rebif)
             for a minimum of 6 months.

        Exclusion Criteria:

          1. Women who are either pregnant or breastfeeding, and women of child-bearing potential
             (defined as not surgically sterile or at least two years post menopausal) who are not
             using one of the following birth control methods: tubal ligation, implantable
             contraception device, oral, patch, injectable or transdermal contraceptive, barrier
             method or sexual activity restricted to vasectomized partner.

          2. Uncontrolled hypertension, clinically significant cardiac arrhythmias,
             gastrointestinal ulcer, uncontrolled diabetes mellitus, osteoporosis, any stage of
             renal failure, psychiatric disorders or any other clinically significant general
             health conditions that may interfere with the trial participation.

          3. Subject has a history of drug or alcohol abuse within the past year.

          4. Subject had corticosteroid treatment within last 90 days.

          5. Subject started new medication within last 30 days.

          6. Subject is on Tysabri treatment presently or within 6 months of screening.

          7. Subject is on Novantrone, Cellcept, Rituxan or other chemotherapeutic treatment
             presently or within 6 months of screening.

          8. Subject is a participant in another research project.

          9. Subject has contraindications for either ACTH or MP administration.
Clinical trial NCT01611688 (phase 1, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: nnc0215-0384, placebo, nnc0215-0384
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints
             and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at
             screening

          -  Concomitant treatment with MTX (7.5 - 25 mg/week both inclusive) for at least 16
             weeks, with a stable dose for at least 6 weeks prior to dosing

        Exclusion Criteria:

          -  Subjects with chronic inflammatory autoimmune disease other than RA

          -  History of or current inflammatory joint disease other than RA such as gout (crystal
             proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive
             arthritis or Lyme disease

          -  Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic
             pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to
             randomisation

          -  Clinically significant cardiac or cardiovascular disease

          -  Past or current malignancy

          -  Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test
             (test can be performed up to 2 months prior to dosing). One retest is allowed in case
             of inconclusive results.- A history of active TB within the last 3 years even, if
             treated effectively. - A history of active TB more than 3 years ago, if there is no
             documentation that the prior anti-TB treatment was appropriate in duration and type
Clinical trial NCT01028261 (phase 1, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: zgn-433
SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Obese, otherwise healthy females

          -  Post menopausal or infertile

          -  Weight ≥ 50 kg

          -  BMI ≥ 32 and ≤ 45 kg/m2

        Exclusion Criteria:

          -  Use of weight loss agents in the past month

          -  History of eating disorder

          -  History of diabetes or other endocrine disorder

          -  History of gastric bypass

          -  Current smokers

          -  Unstable body weight during the past 3 months
Clinical trial NCT00234416 (phase 1/phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gefitinib, gemcitabine
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed pancreatic cancer (aspiration biopsy by fine needle [PAAF] by
             USE or biopsy guide by ECO-CT). It is mandatory the diagnostic by USE and will
             recommend the aspiration biopsy with this technique

          -  Tumoural volume by TAC < 500 cc

          -  Aged 18 to 75 years inclusive

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) £ 1

          -  Life-expectancy of more than 12 weeks

          -  Women of child-bearing potential must be willing to practice reliable methods of birth
             control to prevent pregnancy

        Exclusion Criteria:

          -  Previous radiotherapy or chemotherapy for malignant disease

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or cervical cancer in situ

          -  In the opinion of the investigator, any evidence of severe or uncontrolled systemic
             disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal
             disease)

          -  Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L), platelets less than 100
             x 109/L or haemoglobin less than 9 mg/dL; Prothrombin time (PT) less than 50%; Serum
             bilirubin greater than 2.5 times the upper limit of reference range (ULRR; Creatinine
             clearance less than 45 mL/min; ALT or AST greater than 2.5 times the ULRR

          -  Active dermatoses (e.g. psoriasis, eczema)

          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, or drugs with
             known corneal toxicity

          -  Known, severe hypersensitivity to ZD1839 or any of the excipients of this product